دورية أكاديمية
أعرض في EDS

Hydralazine loaded nanodroplets combined with ultrasound-targeted microbubble destruction to induce pyroptosis for tumor treatment.

التفاصيل البيبلوغرافية
العنوان: Hydralazine loaded nanodroplets combined with ultrasound-targeted microbubble destruction to induce pyroptosis for tumor treatment.
المؤلفون: Huang S; Department of Ultrasound, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China., Shang M; Department of Ultrasound, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China., Guo L; Department of Ultrasound, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China., Sun X; Department of Ultrasound, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China., Xiao S; Department of Ultrasound, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China., Shi D; Department of Ultrasound, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China., Meng D; Department of Ultrasound, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China., Zhao Y; Department of Ultrasound, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China., Wang X; Department of Ultrasound, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China., Liu R; Department of Ultrasound, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China., Li J; Department of Ultrasound, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China. jieli@email.sdu.edu.cn.; Department of Ultrasound, Qilu Hospital (Qingdao) of Shandong University, Qingdao, Shandong, 266035, China. jieli@email.sdu.edu.cn.
المصدر: Journal of nanobiotechnology [J Nanobiotechnology] 2024 Apr 20; Vol. 22 (1), pp. 193. Date of Electronic Publication: 2024 Apr 20.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101152208 Publication Model: Electronic Cited Medium: Internet ISSN: 1477-3155 (Electronic) Linking ISSN: 14773155 NLM ISO Abbreviation: J Nanobiotechnology Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : BioMed Central, 2003-
مواضيع طبية MeSH: Pyroptosis*/physiology , Neoplasms*/drug therapy, Humans ; Microbubbles ; Apoptosis ; Hydralazine/pharmacology ; Hydralazine/therapeutic use
مستخلص: Pyroptosis, a novel type of programmed cell death (PCD), which provides a feasible therapeutic option for the treatment of tumors. However, due to the hypermethylation of the promoter, the critical protein Gasdermin E (GSDME) is lacking in the majority of cancer cells, which cannot start the pyroptosis process and leads to dissatisfactory therapeutic effects. Additionally, the quick clearance, systemic side effects, and low concentration at the tumor site of conventional pyroptosis reagents restrict their use in clinical cancer therapy. Here, we described a combination therapy that induces tumor cell pyroptosis via the use of ultrasound-targeted microbubble destruction (UTMD) in combination with DNA demethylation. The combined application of UTMD and hydralazine-loaded nanodroplets (HYD-NDs) can lead to the rapid release of HYD (a demethylation drug), which can cause the up-regulation of GSDME expression, and produce reactive oxygen species (ROS) by UTMD to cleave up-regulated GSDME, thereby inducing pyroptosis. HYD-NDs combined with ultrasound (US) group had the strongest tumor inhibition effect, and the tumor inhibition rate was 87.15% (HYD-NDs group: 51.41 ± 3.61%, NDs + US group: 32.73%±7.72%), indicating that the strategy had a more significant synergistic anti-tumor effect. In addition, as a new drug delivery carrier, HYD-NDs have great biosafety, tumor targeting, and ultrasound imaging performance. According to the results, the combined therapy reasonably regulated the process of tumor cell pyroptosis, which offered a new strategy for optimizing the therapy of GSDME-silenced solid tumors.
(© 2024. The Author(s).)
References: Nano Converg. 2021 Dec 1;8(1):39. (PMID: 34851458)
Acta Pharmacol Sin. 2022 Oct;43(10):2462-2473. (PMID: 35288674)
Nature. 2017 Jul 6;547(7661):99-103. (PMID: 28459430)
Adv Mater. 2021 Jun;33(22):e2007465. (PMID: 33893682)
J Control Release. 2022 Mar;343:66-77. (PMID: 35085694)
Cell Death Dis. 2020 Apr 27;11(4):295. (PMID: 32341339)
Theranostics. 2022 Jan 1;12(2):817-841. (PMID: 34976215)
Expert Opin Drug Metab Toxicol. 2014 Oct;10(10):1433-44. (PMID: 25154405)
Nano Lett. 2019 Nov 13;19(11):8049-8058. (PMID: 31558023)
N Engl J Med. 2020 Feb 27;382(9):869-871. (PMID: 32101671)
Int J Nanomedicine. 2020 Jan 24;15:537-552. (PMID: 32021193)
Biomaterials. 2019 Oct;217:119299. (PMID: 31254932)
Biomaterials. 2020 Sep;254:120142. (PMID: 32485591)
Theranostics. 2022 May 16;12(9):4310-4329. (PMID: 35673561)
J Control Release. 2020 Mar 10;319:46-62. (PMID: 31846619)
Theranostics. 2020 Jun 25;10(17):7921-7924. (PMID: 32685029)
EBioMedicine. 2019 Mar;41:244-255. (PMID: 30876762)
Int J Pharm. 2022 Feb 5;613:121412. (PMID: 34942327)
J Nucl Med. 2018 May;59(5):740-746. (PMID: 29496981)
J Hematol Oncol. 2022 Dec 8;15(1):174. (PMID: 36482419)
Phytomedicine. 2023 Jan;108:154528. (PMID: 36343549)
Cell Res. 2018 Dec;28(12):1171-1185. (PMID: 30287942)
Cell. 2021 Aug 19;184(17):4495-4511.e19. (PMID: 34289345)
Adv Mater. 2015 Oct 7;27(37):5484-92. (PMID: 26265592)
Pharmaceuticals (Basel). 2021 Jul 13;14(7):. (PMID: 34358096)
Nano Lett. 2022 Oct 26;22(20):8143-8151. (PMID: 36194752)
Front Immunol. 2022 Nov 01;13:1039241. (PMID: 36389728)
Trends Cancer. 2021 May;7(5):392-394. (PMID: 33422423)
Natl Sci Rev. 2021 Jul 30;9(1):nwab137. (PMID: 35087672)
Adv Mater. 2022 Apr;34(16):e2201095. (PMID: 35218106)
Cell Death Discov. 2020 Oct 28;6:112. (PMID: 33133646)
Theranostics. 2020 Mar 15;10(10):4557-4588. (PMID: 32292515)
Cell Res. 2015 Dec;25(12):1285-98. (PMID: 26611636)
Bioact Mater. 2022 May 11;19:642-652. (PMID: 35600972)
Nature. 1992 Jul 9;358(6382):167-9. (PMID: 1614548)
Adv Drug Deliv Rev. 2022 Aug;187:114380. (PMID: 35662610)
Signal Transduct Target Ther. 2020 Aug 24;5(1):159. (PMID: 32839451)
J Clin Oncol. 2016 Mar 20;34(9):987-1011. (PMID: 26846975)
Cell Death Dis. 2019 Feb 25;10(3):193. (PMID: 30804337)
Radiat Prot Dosimetry. 2023 Sep 18;199(14):1441-1449. (PMID: 37721062)
Nature. 2015 Oct 29;526(7575):660-5. (PMID: 26375003)
Angew Chem Int Ed Engl. 2021 Apr 6;60(15):8018-8034. (PMID: 32894628)
Clin Transl Med. 2021 Aug;11(8):e492. (PMID: 34459122)
Chem Biol Interact. 2020 May 25;323:109052. (PMID: 32169591)
Nanomedicine (Lond). 2019 Oct;14(19):2549-2565. (PMID: 31271101)
Acta Biomater. 2019 May;90:337-349. (PMID: 30936037)
Theranostics. 2018 Feb 2;8(5):1327-1339. (PMID: 29507623)
معلومات مُعتمدة: 82071937 National Natural Science Foundation of China
فهرسة مساهمة: Keywords: GSDME; Hydralazine; Nanodroplet; Pyroptosis; Ultrasound-targeted microbubble destruction
المشرفين على المادة: 26NAK24LS8 (Hydralazine)
تواريخ الأحداث: Date Created: 20240420 Date Completed: 20240422 Latest Revision: 20240426
رمز التحديث: 20240426
مُعرف محوري في PubMed: PMC11031971
DOI: 10.1186/s12951-024-02453-0
PMID: 38643134
قاعدة البيانات: MEDLINE
الوصف
تدمد:1477-3155
DOI:10.1186/s12951-024-02453-0